NeuroSense Therapeutics Ltd, a company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into a securities purchase agreement with a single health-care focused institutional investor for the purchase and sale of 2,980,000 ordinary shares in a registered direct offering and ordinary warrants to purchase up to 2,980,000 ordinary shares in a concurrent private placement at a combined purchase price of $1.50 per ordinary share.

The ordinary warrants issued pursuant to the concurrent private placement will have an exercise price of $1.50 per ordinary share, will be immediately exercisable and will expire 5 years from the initial exercise date.